GSK Likes Its Go-It-Alone Strategy Over A Mega-Merger
This article was originally published in The Pink Sheet Daily
Executive Summary
GlaxoSmithKline’s solo strategy is the right one, CEO Andrew Witty said, brushing aside questions about a potential merger with Pfizer during the company’s third quarter sales and earnings call.
You may also be interested in...
Swapping Assets Now Down To Execution For GSK And Novartis
Being successful with products originally marketed by the other will be key to the future growth and bragging rights for two leading European Big Pharmas, GlaxoSmithKline and Novartis.
GSK’s Darapladib Poised To Become Latest Cardiovascular Outcomes Casualty
Company announces that Lp-PLA2 inhibitor darapladib fails Phase III STABILIITY outcomes study, the latest in a string of pharma CV failures.
Radius Business Review Ends In Sale To Investment Funds
Gurnet Point Capital and Patient Square Capital will buy Radius Health for approximately $890m, including a contingent value right dependent on sales growth for osteoporosis drug Tymlos.